2020 TCT | Transplantation & Cellular Therapy Meetings
Abstract 413: A Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ Transplant Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease (EBV+PTLD) after Failure of Rituximab or Rituximab and Chemotherapy
Poster Presentation Date and Time: Saturday, February 22, 2020; 6:15 - 7:45 p.m. EST
Session Title: Poster Session II: Cellular and Gene Therapy: Clinical/Processing
Location: World Center Marriott - Palms & Cypress Foyers
Authors: Susan Prockop, M.D.1, Minoti Hiremath, MBBS, Ph.D.2, Wei Ye, Ph.D.2, Laurence Gamelin, Ph.D.2, Willis H. Navarro, M.D.2, Kris Michael Mahadeo, M.D.3
Affiliations: 1Memorial Sloan Kettering Cancer Center, New York, NY; 2Atara Biotherapeutics, South San Francisco, CA; 3MD Anderson Cancer Center, Houston, TX